The trial assesses Precem-TcT efficacy and safety alone or with bevacizumab in mCRC patients after previous therapies.
In Pivotal Phase III Studies, Merck’s Investigational Medicine Boceprevir Helped Majority of Patients with Chronic Hepatitis C Genotype 1 Infection Achieve Sustained Virologic Response, the Primary ...
Merck KGaA, Darmstadt, Germany, Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in ...
Biotech’s antibody-drug conjugate significantly improved progression-free and overall survival in a pivotal endometrial ...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new analyses from studies of sotatercept, Merck’s novel investigational activin ...
Merck (MRK), known as MSD outside the United States and Canada, today announced new data for suvorexant, the investigational medicine Merck is developing for the treatment of insomnia. The new data ...
KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced data from six preclinical studies ...
When Merck announced it would spin out its women’s health and off-patent drugs into a new standalone business, the pharmaceutical giant said the new company would also have the capacity to add new ...
What will Keytruda's trajectory look like through 2029? The medicine's sales should continue growing until 2028, when it will hit peak sales above $30 billion, according to some estimates. However, ...
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE ®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results